266
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

, , , & ORCID Icon
Pages 3507-3510 | Received 20 Jun 2020, Accepted 04 Aug 2020, Published online: 24 Aug 2020
 

Disclosure statement

GCH reports stock ownership of Bristol-Myers Squibb

Informed consent

The patient described has given consent to the inclusion of material pertaining to herself, acknowledges that she is not identifiable via the paper. We have fully anonymized the patient.

Additional information

Funding

GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.